RepSox Slows Decay of CD34(+) Acute Myeloid Leukemia Cells and Decreases T Cell Immunoglobulin Mucin-3 Expression

Despite initial response to therapy, most acute myeloid leukemia (AML) patients relapse. To eliminate relapse-causing leukemic stem/progenitor cells (LPCs), patient-specific immune therapies may be required. In vitro cellular engineering may require increasing the “stemness” or immunogenicity of tum...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Jajosky, Audrey N., Coad, James E., Vos, Jeffrey A., Martin, Karen H., Senft, Jamie R., Wenger, Sharon L., Gibson, Laura F.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: AlphaMed Press 2014
Aiheet:
Cancer Stem Cells
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4073822/
https://ncbi.nlm.nih.gov/pubmed/24855276
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5966/sctm.2013-0193
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia